Introduction: Who Should Undergo Diagnostics

Anyone experiencing persistent bone pain, swelling, or a lump that doesn’t go away should seek medical attention promptly. Metastatic Ewing’s sarcoma most commonly affects adolescents and young adults, typically between the ages of 10 and 20, though it can occur at any age.^[1] The word metastatic means the cancer has spread from where it originally started to other parts of the body, most often to the lungs, other bones, or bone marrow.^[7]

Parents and caregivers should be particularly alert if a child or teenager complains of bone pain that worsens at night, develops unexplained fever, experiences weight loss without trying, or shows swelling near a bone that feels warm to the touch.^[1] These symptoms can sometimes be mistaken for sports injuries or growing pains, which is why persistent symptoms warrant a thorough medical evaluation. The earlier a diagnosis is made, the sooner appropriate treatment can begin.

Young people who develop a lump in their arm, leg, chest, or pelvis should not dismiss it as a simple bruise or bump. If the area becomes increasingly painful, limits movement, or doesn’t improve over several weeks, diagnostic testing becomes advisable.^[7] Ewing sarcoma can also cause breaks in bones that happen without any injury, which is an alarming sign that requires immediate medical attention.^[1]

Doctors typically recommend diagnostic workup when symptoms persist for more than two weeks or when they interfere with daily activities. Because metastatic Ewing’s sarcoma is aggressive and can progress quickly, timely recognition and diagnosis are essential to reduce the risk of complications and improve survival chances.^[3]

Diagnostic Methods for Identifying the Disease

The diagnostic journey for metastatic Ewing’s sarcoma begins with a physical examination where the doctor checks for lumps, swelling, tenderness, and any unusual signs. The healthcare provider will also take a detailed medical history, asking about symptoms, their duration, and any family history of disease.^[10] This initial assessment helps determine which tests are needed next.

Imaging Tests

Imaging tests create detailed pictures of the inside of the body and are fundamental for locating tumors and understanding their size and spread. X-rays are often the first imaging test performed when bone pain or swelling is present. An X-ray can show abnormal areas in bones that might indicate a tumor.^[10] However, X-rays alone cannot confirm a diagnosis of Ewing’s sarcoma or determine if it has spread.

Magnetic resonance imaging, or MRI, uses magnets and radio waves to create detailed images of soft tissues and bones. This test is particularly useful for seeing the extent of the primary tumor and how it affects nearby tissues like muscles, tendons, and blood vessels.^[4] MRI scans help surgeons plan how to remove the tumor safely.

Computed tomography, commonly called a CT scan, combines multiple X-ray images taken from different angles to create cross-sectional views of bones and soft tissues. CT scans are especially important for detecting whether Ewing’s sarcoma has spread to the lungs, which is the most common site of metastasis.^[10] Because lung involvement significantly affects treatment decisions and prognosis, a chest CT scan is typically part of the diagnostic workup for all Ewing’s sarcoma patients.

A bone scan is a nuclear medicine test that involves injecting a small amount of radioactive material into a vein. This material travels through the bloodstream and collects in areas of bone where cancer may be present. A special camera then takes pictures of the skeleton to identify abnormal areas that might indicate cancer spread to other bones.^[10] This test is valuable for finding metastatic disease that may not show symptoms yet.

Positron emission tomography, or PET scan, is another nuclear medicine imaging test that can detect cancer cells throughout the body. During a PET scan, a small amount of radioactive sugar is injected into the body, and cancer cells, which use more sugar than normal cells, show up as bright spots on the scan.^[10] PET scans are particularly useful for identifying metastatic disease and can sometimes be combined with CT scans for more detailed information.

Biopsy: The Definitive Test

While imaging tests can show suspicious areas, a biopsy is the only way to definitively confirm a diagnosis of Ewing’s sarcoma. A biopsy involves removing a sample of tissue from the tumor so it can be examined under a microscope by a specialist called a pathologist.^[10] There are different ways to perform a biopsy, depending on where the tumor is located.

Sometimes the tissue sample can be obtained using a needle that is inserted through the skin and into the tumor. This is called a needle biopsy. In other cases, surgery may be needed to get an adequate tissue sample. The biopsy must be performed carefully by an experienced orthopedic surgeon or oncologic surgeon, because the biopsy site must later be removed during definitive surgery to prevent cancer spread.^[10]

Once the tissue sample reaches the laboratory, pathologists examine it to determine if cancer cells are present and what type they are. Special laboratory tests are performed on the cancer cells to look for specific genetic changes. Ewing’s sarcoma cells have characteristic changes involving the EWSR1 gene, which is found on chromosome 22. In about 85 percent of cases, this gene joins with another gene called FLI1 to create a fusion gene called EWS-FLI1.^[3] In another 10 to 15 percent of cases, EWSR1 joins with a gene called ERG to create an EWS-ERG fusion.^[3]

Testing the tumor cells for these gene changes is critical because it confirms the diagnosis of Ewing’s sarcoma and helps distinguish it from other types of cancer that may look similar under the microscope.^[10] This genetic testing is now considered a standard part of the diagnostic process.

Determining the Extent of Metastatic Disease

Once Ewing’s sarcoma is confirmed, additional testing determines whether the cancer has spread and, if so, how extensively. This process is called staging. For Ewing’s sarcoma, staging is simpler than for many other cancers. The disease is classified as either localized or metastatic.^[7]

Localized disease means the tumor has not spread beyond where it started or the tissues immediately surrounding it. Metastatic disease means the cancer has spread to distant parts of the body, such as the lungs, other bones, or bone marrow. About 25 percent of patients with Ewing’s sarcoma present with obvious metastatic disease at diagnosis.^[5] However, as mentioned earlier, most patients likely have microscopic metastatic disease even when scans appear clear.

Tests used to detect metastatic disease include chest CT scans to check the lungs, bone scans or PET scans to check other bones throughout the skeleton, and sometimes bone marrow biopsies to see if cancer cells have reached the bone marrow.^[4] These tests are usually done at the same time as the initial diagnostic tests so that doctors have a complete picture before starting treatment.

Laboratory Tests

Blood tests are also part of the diagnostic workup, though they cannot diagnose Ewing’s sarcoma by themselves. Routine blood tests check overall health, organ function, and blood cell counts. Sometimes patients with Ewing’s sarcoma have elevated markers of inflammation or anemia, but these findings are not specific to this cancer.^[4] Blood tests help doctors understand the patient’s general condition and plan treatment safely.

Diagnostics for Clinical Trial Qualification

Clinical trials are research studies that test new treatments or combinations of treatments to find better ways to manage Ewing’s sarcoma. Participating in a clinical trial may give patients access to innovative therapies that are not yet widely available. However, to enroll in a clinical trial, patients must meet specific criteria, and certain diagnostic tests are required to determine eligibility.^[6]

Standard diagnostic criteria for clinical trials typically include confirmation of the diagnosis through biopsy with genetic testing showing the characteristic EWSR1 gene fusion. Imaging tests including chest CT, bone scan or PET scan, and MRI of the primary tumor site are usually required to document the extent of disease at the start of the trial.^[4] These baseline images allow researchers to measure how well the treatment is working by comparing them to scans taken later.

Blood tests to assess organ function are essential for clinical trial enrollment because many cancer treatments can affect the liver, kidneys, heart, and bone marrow. Trials typically require that these organs are functioning well enough to tolerate the planned treatment. Tests may include liver function tests, kidney function tests, blood counts, and sometimes heart function tests like an echocardiogram or electrocardiogram.^[4]

Some clinical trials test treatments specifically for metastatic Ewing’s sarcoma, while others compare different chemotherapy regimens or investigate the addition of new drugs to standard treatment. The diagnostic tests required depend on the specific trial, but the goal is always to ensure that the patient truly has the disease being studied and that they can safely receive the experimental treatment.

Age, performance status (how well the patient can perform daily activities), and previous treatments may also affect trial eligibility. Patients interested in clinical trials should discuss options with their oncology team, who can help identify appropriate studies and coordinate the necessary diagnostic testing.